MDS Prognosis - Understanding IPSS and IPSS-R Scores 2018

(54:1econd)

IPSS-R vs IPSS-M for MDS

(1:39)

6-Molecular prognostic scoring (IPSS-M) – How does it improve patient management?

(16:7)

What is the difference between the IPSS and the IPSS-R?

(4:2)

Prognosis in Myelodysplastic syndromes - using the IPSS (Advanced)

(15:58)

#280 Development and Pilot Testing of a Simplified Version of the International Prostate Symptom...

(4:31)

#413 The first qualitative study into the comprehensibility of the IPSS and two visual alternati...

(5:)

Benefits, applicability \u0026 uses of the IPSS-M in MDS

(2:23)

Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

(13:13)

Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS \u0026 spliceosome mutations

(1:30)

IPSS testing by Dr KD Jarial

(11:)

What is the 7-question IPSS test?

(1:24)

#684 COMPARISON OF IPSS AND ICIQ MLUTS SCORES IN MEN WITH VOIDING LOWER URINARY TRACT SYMPTOMS

(7:33)

Evaluating IPSS-R and IPSS-M in patients with HR-MDS enrolled in STIMULUS-MDS1 and STIMULUS-MDS2

(1:45)

Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era

(3:31)

The IPSS Shelved or Disengaged

(13:26)

What is Benign Prostatic Hyperplasia (BPH)?

(1:7)

Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT

(6:4)

Diagnosing and Treating Pituitary Tumors - California Center for Pituitary Disorders at UCSF

(2:34)